Abstract
Introduction. The influenza vaccine as the most effective method for preventing influenza virus infection currently has lower efficacy in the elderly than younger adults due to change of immune response as well as other risk factors. This study aims to identify predictor factors affecting seroconversion post-influenza vaccination in elderly. Methods. retrospective cohort study in the elderly population in East Jakarta Posyandu who got the influenza vaccine. A total of 277 subjects with antibody titre pre and one month post-vaccination influenza were examined. Risk factors such as age, gender, exercise status, smoking status, type 2 diabetes, pulmonary, and cardiovascular disease, nutritional status of MNA (Mini Nutritional Assessment), GDS (Geriatric Depression Scale), and pre-vaccination antibodi titre were assessed in each subject. Results. The proportion of elderly people who seroconverted (fourfold rise or more in antibody titer post-vaccination) was 50.9% (141/277). On multivariate analysis, the predictor factors that affect seroconversion of one month post- influenza vaccination in the elderly on the community is a no depression state (p = 0.048, OR = 2.1, CI = 1.01 to 4.30), exercise status ≥5 times per week minimal 30 minutes (p = 0.013, OR 4.0, CI 1.34 to 11.76), and not seroprotective pre-vaccination (p=0.000, OR 6.4, CI 3.40 to 11.99). Conclusion. Predictor factors affecting seroconversion post-influenza vaccination in the elderly on the community is depression status, exercise status and pre-vaccination antibody titre.
References
1. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24(8):1159–69. 2. Lazuardi L, Jenewein B, Wolf AM, Pfister G, Tzankov A, GrubeckLoebenstein B. Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology. 2005;114(1):37–43. 3. Muszkat M, Friedman G, Dannenberg HD, Greenbaum E, Lipo M, Heymann Y, et al. Response to influenza vaccination in community and in nursing home residing elderly: relation to clinical factors. Exp Gerontol. 2003;38(10):1199–203. 4. Busse WW, Peters SP, Fenton MJ, Mitchell H, Bleecker ER, Castro M, et al. Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. J Allergy Clin Immunol. 2011;127(1):130–7. 5. Kaml M, Weiskirchner I, Keller M, Luft T, Hoster E, Hasford J, et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine. 2006;24(47-48):6808–11. 6. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008;198(5):650– 8. 7. Fülöp T, Larbi A, Hirokawa K, Mocchegiani E, Lesourd B, Castle S, et al. Immunosupportive therapies in aging. Clin Interv Aging. 2007;2(1):33–54. 8. O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007;6(5):699–710. 9. Licciardi PV, Tang MLK. Vaccine adjuvant properties of probiotic bacteria. Discov Med. 2011;12(67):525–33. 10. High KP. Micronutrient supplementation and immune function in the elderly. Clin Infect Dis Off Publ Infect Dis Soc Am. 1999;28(4):717–22. 11. U.S. Department of Health and Human Services. Guidance for Industry Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. Food and Drug Administration Center for Biologics Evaluation and Research; 2007. 12. Adi S, Novida H, Rudijanto A, Soewondo P. Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2015. PB PERKENI; 2015.Committee for proprietary medicinal products. Note for guidance on harmonisation of requirements for influenza vaccines. London; 1997. 13. Wilkins LW&. Physical Activity and Public Health in Older Adults. Circulation. 2007 Aug 28;116(9):1094–105. 14. US Food and Drug Administration (FDA). Statistical review and evaluation influenza vaccine. USA: FDA; 2005. 15. Kiecolt-Glaser JK, Glaser R, Gravenstein S, Malarkey WB, Sheridan J. Chronic stress alters the immune response to influenza virus vaccine in older adults. Proc Natl Acad Sci. 1996;93(7):3043–7. 16. Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res. 2002;53(4):873–6. 17. Woods JA, Keylock KT, Lowder T, Vieira VJ, Zelkovich W, Dumich S, et al. Cardiovascular exercise training extends influenza vaccine seroprotection in sedentary older adults: the immune function intervention trial. J Am Geriatr Soc. 2009;57(12):2183–91. 18. Matsushita M, Takeuchi S, Kumagai N, Uehara Y, Matsushita C, Arise K, et al. Prevaccination antibody titers can estimate the immune response to influenza vaccine in a rural community-dwelling elderly population. Vaccine. 2012;30(6):1101–7.
Recommended Citation
Nursyirwan, Saskia Aziza; Koesnoe, Sukamto; and Wahyudi, Edy Rizal
(2017)
"Predictor Factors Affecting Seroconversion Post-InfluenzaVaccination in the Elderly,"
Jurnal Penyakit Dalam Indonesia: Vol. 4:
Iss.
4, Article 7.
DOI: 10.7454/jpdi.v4i4.159
Available at:
https://scholarhub.ui.ac.id/jpdi/vol4/iss4/7